Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures.
An oligonucleotide (T30177) composed entirely of deoxyguanosine and thymidine has previously been shown to fold upon itself in the presence of potassium into a highly stable four-stranded DNA structure containing two stacked deoxyguanosine quartets (G4s). T30177 also protects host cells from the cytopathic effects of human immunodeficiency virus type 1 (HIV-1). We report that this G4 oligonucleotide is the most potent inhibitor of HIV-1 integrase identified to date, with IC50 values in the nanomolar range. Both the number of quartets formed and the sequence of the loops between the quartets are important for optimal activity. T30177 binds to HIV-1 integrase without being processed and blocks the binding of the normal viral DNA substrate to the enzyme. The normal DNA substrate was not able to compete off T30177 binding to HIV-1 integrase, indicating a tight binding of G4s to the enzyme. Experiments with truncated HIV-1 integrases indicate that the N-terminal region containing a putative zinc finger is required for inhibition by T30177 and that T30177 binds better to full-length or deletion mutant integrases containing the zinc finger region than to a deletion mutant consisting of only the central catalytic domain. The N-terminal region of integrase alone is able to bind efficiently to T30177, but not the linear viral DNA substrate, in the presence of zinc. Hence, G4s represent the first class of compounds that inhibit HIV-1 integrase by interacting with the enzyme N-terminal domain. The greater inhibitory potency of T30177 in buffer containing magnesium versus manganese suggests that divalent metal ion coordination along the phosphodiester backbone may play a role in the inhibitory activity. T30177 inhibited HIV-2 integrase with similar potency as HIV-1 but inhibited feline and simian immunodeficiency virus integrases at higher concentrations, suggesting selectivity can be achieved. We propose that novel AIDS therapies could be based upon guanosine quarters as inhibitors of HIV-1 integrase.
Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, Maryland 20892-4255, USA.
A
A
Mazumder
N
N
Neamati
J O
JO
Ojwang
S
S
Sunder
R F
RF
Rando
Y
Y
Pommier
D001667:Binding, Competitive; D003432:Cross-Linking Reagents / Q000378:metabolism; D004247:DNA / Q000378:metabolism; D004268:DNA-Binding Proteins; D003839:Deoxyadenosines / Q000378:metabolism; D003849:Deoxyguanosine / Q000031:analogs & derivatives*; D004591:Electrophoresis, Polyacrylamide Gel; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology; D019428:HIV Integrase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D015497:HIV-1 / Q000201:enzymology*; D015498:HIV-2 / Q000201:enzymology; D016089:Immunodeficiency Virus, Feline / Q000201:enzymology; D008274:Magnesium / Q000494:pharmacology; D008345:Manganese / Q000494:pharmacology; D009154:Mutation / Q000235:genetics; D009838:Oligodeoxyribonucleotides / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D009841:Oligonucleotides / Q000494:pharmacology; D017384:Sequence Deletion / Q000235:genetics; D014466:Ultraviolet Rays; D016335:Zinc Fingers / Q000235:genetics
D003432:Cross-Linking Reagents; D004268:DNA-Binding Proteins; D003839:Deoxyadenosines; D004791:Enzyme Inhibitors; D019428:HIV Integrase Inhibitors; D009838:Oligodeoxyribonucleotides; D009841:Oligonucleotides; D008345:Manganese; D004247:DNA; C098172:T 30177; D003849:Deoxyguanosine; C058120:cordycepin; D008274:Magnesium